Association of Human Herpesvirus 6 and 8 in Relapsing Remitting Multiple Sclerosis Type during Exacerbation
Hassan Salama, Mohamed El-Khateeb, Rawya Bader, Mohamed Saleh, Enas Hamad
DOI: 10.4236/nm.2010.11005   PDF    HTML     4,122 Downloads   7,820 Views  


Multiple Sclerosis (MS) is a chronic demyelinating disease of the CNS with assumed autoimmune etiology. Human herpes viruses have probable effects on relapsing-remitting MS pathogenesis presumably through molecular mimicry and/or bystander mechanisms. In this study we probed the possible contribution of the two herpes viruses, human herpesvirus 6 (HHV-6) and human herpesvirus 8 (HHV-8), in clinically definite multiple sclerosis (CDMS) pa-tients-relapsing remitting type (RRMS) during clinical exacerbations. All patients had no history of immune modulating or suppressing drugs intake in the last 6 months. The peripheral blood samples, from CDMS patients (n = 20) (13F/7M, age (y) = 30.3 ± 3.21) and other immune mediated neurological disorders (OIND) (11F/9M, age = 25.2 ± 12.1), (My-asthenia Gravis, Guillain Barré Syndrome, ischemic stroke in adolescent and young adult with no clear risk factors), as a control group, had been enrolled within 15 months (January-2007-- March -2008). We investigated the existence of specific deoxyribonucleic acid (DNA) sequences belonging to HHV-6 and HHV-8, using polymerase chain reaction (PCR) in the isolated peripheral blood mononuclear cells (PBMCs) and in plasma. PCR demonstrated HHV-6 DNA in 7 cases (35%), HHV-8 sequences in only one cases (5%) in PBMCs from 20 relapsed CDMS patients; all HHV-6 posi-tive cases showed positive plasma results, while the blood samples from 20 OIND patients showed negative results ex-cept one case (5%) out of 9 cases of GBS was positive for HHV-8 in PBMCs. We consequently concluded that there is considerable evidence in this study that proposed the roles of HHV-6 and HHV-8 in MS pathogenesis and clinical ex-acerbation.

Share and Cite:

H. Salama, M. El-Khateeb, R. Bader, M. Saleh and E. Hamad, "Association of Human Herpesvirus 6 and 8 in Relapsing Remitting Multiple Sclerosis Type during Exacerbation," Neuroscience and Medicine, Vol. 1 No. 1, 2010, pp. 33-37. doi: 10.4236/nm.2010.11005.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. E. McFarlin and H. F. McFarland, “Multiple Sclerosis,” The New England Journal of Medicine, Vol. 307, 1982, pp. 1183-1188.
[2] J. E. Friedman, M. J. Lyons, G. Cu, D. V. Ablashl, J. E. Whitman, M. Edgar, M. Koskiniemi, A. Vaheri and J. B. Zabriskie, “The Association of the Human Herpesvirus-6 and MS,” Multiple Sclerrosis, Vol. 5, No. 5, pp. 355-362.
[3] H. Lassmann, “Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis,” Springer Verlag, Berlin, 1983.
[4] J. F. Kurtzke, “Epidemiological Evidence for Multiple Sclerosis as an Infection,” Clinical Microbiology Review, Vol. 6, No. 4, 1993, pp. 382-427.
[5] S. S. Solden, R. Berti, N. Salem, et al., “Association of Human Herpes Virus 6 (HHV-6) With Multiple Sclerosis: Increased Igm Response to HHV-6 Early Antigen and Detection of Plasma HHV-6 DNA,” Nature Medicine, Vol. 3, 1997, pp. 1394-1397.
[6] S. F. Hunterand D. A. Hafler, “Ubiquitous Pathogens. Links between Infection and Autoimmunity in MS,” Neurology, Vol. 55, No. 2, 2000, pp. 164-165.
[7] A. K. Abbas, K. M. Murphy and A. Sher, “Functional Diversity of Helper T Lymphocytes,” Nature, Vol. 383, No. 6603, 1996, pp. 787-793.
[8] M. Allegretta, J. A. Nicklas and S. Sriram, R. J. Albertini and O. T. Abramsky, “Cells Responsive to Myelin Basic Protein in Patients with Multiple Sclerosis,” Science, Vol. 247, No. 4943, 1990, pp. 718-721.
[9] K. Bandobashi, M. Daibata, M. Kamioka, Y. Tanaka, I. Kubonishi, H. Taguchi, Y. Ohtsuki and I. Miyoshi, “Human Herpesvirus 6 (HHV-6)-Positive Burkitt’s Lymphoma: Establishment of a Novel Cell Line Infected with HHV-6,” Blood, Vol. 90, No. 3, 1997, pp. 1200-1207.
[10] W. L. McDonald, D. A. S. Compston, G. Edan, D. E. Goodkin, H. P. Hartung, F. D. Lublin, et al., “Diagnostic Criteria for MS: Guidelines from the International Panel on the Diagnosis of MS,” Annals of Neurology, Vol. 50, No. 1, 2001, pp. 121-127.
[11] C. M. Poser, D. W. Paty, L. Scheinberg, W. I. McDonald, F. A. Davis, G. C. Ebers, et al., “New Diagnostic Criteria for Multiple Sclerosis: Guidelines for Research Protocols,” Ann Neurol, Vol. 13, No. 2, pp. 227-231.
[12] S. Beer, K. M. R?sler and C. W. Hess, “Diagnostic Value of Paraclinical Tests In Multiple Sclerosis: Relative Sensitivities and Specificities for Reclassification According to the Poser Committee Criteria,” Journal of Neurology Neurosurgery Psychiatry, Vol. 59, No. 2, pp. 152-159.
[13] M. L. Opsahl and P. G. Kennedy, “Investigating the Presence of Human Herpesvirus 7 And 8 in Multiple Sclerosis and Normal Control Brain Tissue,” Journal of the Neurological Sciences, Vol. 240, No. 1-2, pp. 37-44.
[14] A. Simmons, “Herpesvirus and Multiple Sclerosis,” Herpes, Vol. 8, No. 3, pp. 60-63.
[15] E. Norrby, H. Link and J. E. Olsson. “Comparison of Antibodies Against Different Viruses in Cerebrospinal Fluid and Plasma Samples from Patients with Multiple Sclerosis,” Infect Inmunology, Vol. 10, 1974, pp. 688.
[16] R. T. Johnson, “The Virology of Demyelinating Diseases,” Annals Neurology, Vol. 36, 1994, pp. 54-60.
[17] C. Martin, M. Enbom, M. S?derstr?m, S. Fredrikson, H. Dahl, J. Lycke, et al., “Absence of Seven Human Herpesviruses, Including HHV-6, By Polymerase Chain Reaction In CSF And Blood From Patients With Multiple Sclerosis And Optic Neuritis,” Acta Neurological Scandinavica, Vol. 95, No. 5, 1997, pp. 280-283.
[18] M. Enbom, F. Z. Wang, S. Fredrikson, C. Martin, H. Dahl and A. Linde, “Similar Humoral and Cellular Immunological Reactivities to Human Herpesvirus 6 in Patients with Multiple Sclerosis and Controls,” Clinical Diagnostic Lab Immunology, Vol. 6, No. 4, 1999, pp. 545-549.
[19] M. Enbom, “Multiple Sclerosis and Kaposi’s Sacoma- Chronic Diseases Associated with New Human Herpesviruses?” Scandinavial Journal Infectious Diseases, Vol. 33, No. 9, 2001, pp. 648-658.
[20] K. K. Knox, D. Harrington and D. R. Carrigan, “Active Human Herpesvirus Type 6 Infections are Present in the Central Nervous System, Lymphoid Tissues and Peripheral Blood of Patients with Multiple Sclerosis,” Annals Neurology, Vol. 44, 1998, p. 485.
[21] M. Mayne, J. Krishnan, L. Metz, et al., “Infrequent Detection of Human Herpesvirus 6 DNA in Peripheral Blood Mononuclear Cells from Multiple Sclerosis Patients,” Annals Neurology, Vol. 44, No. 3, 1998, pp. 391- 394.
[22] E. Merelli, R. Bedin, P. Sola, P. Barozzi, G. L. Mancardi, G. Ficarra et al., “Human Herpes Virus 6 and Human Herpes Virus 8 DNA Sequences in Brains of Multiple Sclerosis Patients, Normal Adults and Children,” Journal Neurology, Vol. 244, No. 7, 1997, pp. 450-454.
[23] K. Felgenhauer and H.Reiber, “The Diagnostic Significance of Antibody Specificity Indices in Multiple Sclerosis and Herpesvirus Induced Diseases of the Nervous System,” The Journal of Clinical Investigation, Vol. 70, No. 1, 1992, pp. 28-37.
[24] A. Rotola, E. Cassai, M. R. Tola, E. Granieri and D. Di Luca, “Human Herpesvirus 6 is Latent in Peripheral Blood of Patients with Relapsing-Remitting Multiple Sclerosis,” Journal of Neurology Neurosurgery Psychiatry, Vol. 67, No. 4, pp. 529-531.
[25] J. Lycke, B. Svennerholm, E. Hjelmquist, et al., “Acyclovir Treatment of Relapsing Remitting Multiple Sclerosis. Randomized Placebo-Controlled, Double-Blind Study,” Journal Neurology, Vol. 243, No. 3, pp. 214-224.
[26] K. R. Beutner, “Valacyclovir: A Review of Its Antiviral Activity, Pharmacokinetic Properties, and Clinical Efficacy,” Antiviral Research, Vol. 28, No. 4, 1995, pp. 281- 290.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.